WNK2 and thyroid gland carcinoma: All these mutations potentially lead to upregulation of the RAS/BRAF/mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase (MEK)/ERK or MAPK pathway that is involved in thyroid cancer.